Showing results (171-180 of 212) with videos related to

Sort By:
Pageof 22
Leukemia Research|February 8, 2017
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AMLAminetou Mint Mohamed, Marie Balsat, Catherine Koering, et al.
Blood|February 21, 2012
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesFrederik Damm, Olivier Kosmider, Véronique Gelsi-Boyer, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Blood|October 24, 2002
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)Christophe Roumier, Virginie Eclache, Michelle Imbert, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
Blood|September 25, 2003
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951Hélène Cavé, Stefan Suciu, Claude Preudhomme, et al.
Blood Advances|March 9, 2021
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesisFlorian Renosi, Anne Roggy, Ambre Giguelay, et al.
The Lancet. Haematology|July 21, 2024
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trialMaría Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association groupMaxime Janin, Elena Mylonas, Véronique Saada, et al.
Blood|August 19, 2021
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapyRaphael Itzykson, Elise Fournier, Céline Berthon, et al.
Pageof 22